List of Excipients in Branded Drug LEVETIRACETAM IN SODIUM CHLORIDE

« Back to Dashboard

Generic Drugs Containing LEVETIRACETAM IN SODIUM CHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	levetiracetam in sodium chloride	0143-9281	ACETIC ACID
Hikma Pharmaceuticals USA Inc	levetiracetam in sodium chloride	0143-9281	SODIUM ACETATE
Hikma Pharmaceuticals USA Inc	levetiracetam in sodium chloride	0143-9281	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	levetiracetam in sodium chloride	0143-9281	WATER
Nexus Pharmaceuticals LLC	levetiracetam	14789-110	ACETIC ACID
Nexus Pharmaceuticals LLC	levetiracetam	14789-110	SODIUM ACETATE
Nexus Pharmaceuticals LLC	levetiracetam	14789-110	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in LEVETIRACETAM IN SODIUM CHLORIDE?

# Of NDCs	Excipient
2	ACETIC ACID
2	SODIUM ACETATE
2	SODIUM CHLORIDE
1	WATER
1	WATER O-18

Levetiracetam in Sodium Chloride: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 21, 2026

Levetiracetam in sodium chloride injection is a mature generic hospital product with limited formulation-patent protection and strong demand for reliable ready-to-use intravenous supply. The commercial opportunity is not based on novel excipient claims. It is based on manufacturing efficiency, container-closure differentiation, stability, pharmacy workflow, shortage resilience, and contracting access.

The formulation is comparatively simple: levetiracetam, sodium chloride, Water for Injection, and pH-adjusting agents where required. The main technical risks are chemical stability, particulate control, container compatibility, extractables and leachables, osmolality, pH control, and reliable supply of sterile single-dose bags or vials. The main commercial risks are low unit prices, multiple generic competitors, hospital purchasing pressure, and limited opportunity to obtain meaningful exclusivity.

What is levetiracetam in sodium chloride injection?

Levetiracetam in sodium chloride injection is an intravenous formulation of the antiepileptic drug levetiracetam, usually supplied as a ready-to-use infusion bag. It is used when oral administration is temporarily unavailable or inappropriate.

Typical commercial strengths include:

Product attribute	Common configuration
Active ingredient	Levetiracetam
Dosage form	Sterile intravenous solution
Diluent	0.9% sodium chloride
Common strengths	500 mg/100 mL, 1,000 mg/100 mL, 1,500 mg/100 mL
Concentration	Often 5 mg/mL, 10 mg/mL, or 15 mg/mL
Administration	Intravenous infusion
Container	Flexible infusion bag or vial
Preservatives	Generally absent in single-dose presentations
Regulatory category	Small-molecule generic drug
Biosimilar exposure	None

Levetiracetam injection is commonly administered over approximately 15 minutes, although the approved label controls the specific preparation and administration instructions. Ready-to-use presentations reduce pharmacy compounding and dilution steps compared with a concentrate.

The FDA-approved reference product, Keppra injection, established the core intravenous dosage form. Multiple abbreviated new drug applications have since entered the market. Current product labeling should control dosage, storage, compatibility, and handling decisions for each manufacturer because excipient levels and container systems can differ.[1-3]

What excipients are used in levetiracetam sodium chloride injection?

The core excipient strategy is a low-complexity aqueous system designed to avoid unnecessary formulation variables.

Excipient or formulation component	Primary function	Commercial and technical relevance
Sodium chloride	Isotonicity and infusion vehicle	Supports peripheral or central intravenous administration when the final osmolality is acceptable
Water for Injection	Solvent	Must meet compendial sterile water requirements
Hydrochloric acid	pH adjustment	Controls pH during manufacture
Sodium hydroxide	pH adjustment	May be used to raise pH or fine-tune the formulation
Container-contact materials	Packaging system	Can affect stability, sorption, leachables, and shelf life

A formulation may contain only sodium chloride and pH adjusters as inactive ingredients. The exact inactive-ingredient profile should be verified against the applicable FDA label and the manufacturer’s Chemistry, Manufacturing, and Controls dossier.

Why is the excipient platform deliberately narrow?

Levetiracetam is highly water-soluble, so the formulation generally does not require a cosolvent, surfactant, lipid vehicle, complexing agent, or solubilizing polymer. Adding such components could increase regulatory burden and introduce new risks without improving clinical performance.

A narrow excipient platform can reduce:

• Toxicological qualification work
• Extractables and leachables investigations
• Compatibility testing
• Sterilization-related degradation
• Labeling complexity
• Raw-material procurement risk
• Change-control requirements

The formulation objective is therefore not to maximize excipient innovation. It is to achieve the required concentration, pH, osmolality, sterility assurance, stability, and container compatibility with the fewest components.

What formulation attributes matter most for commercial development?

The most valuable formulation attributes are operational rather than pharmacological.

Ready-to-use administration

A premixed bag can eliminate pharmacy dilution from a concentrate. This reduces preparation time and may reduce compounding-related medication errors. Hospitals may assign value to a product that can move directly from storage to administration with limited manipulation.

Preservative-free presentation

Single-dose intravenous bags generally avoid antimicrobial preservatives. This supports broad hospital use and simplifies the safety profile for a product intended for direct infusion.

Concentration selection

A manufacturer can compete through a portfolio of concentrations rather than a new active formulation.

Concentration strategy	Potential advantage	Main limitation
5 mg/mL	Lower concentration and broad infusion familiarity	Larger administration volume
10 mg/mL	Balanced volume and dosing flexibility	Requires adequate stability and container performance
15 mg/mL	Lower infusion volume	Higher concentration increases formulation and administration scrutiny
Multiple bag sizes	Supports different hospital protocols	Increases manufacturing and inventory complexity

A commercial program should prioritize concentrations that match hospital order sets and common loading-dose requirements. The value of an additional strength depends on purchasing data, not simply on technical feasibility.

pH and osmolality control

pH affects chemical stability, patient tolerability, container compatibility, and the performance of analytical methods. Osmolality affects infusion handling and the suitability of peripheral administration.

The optimal target is not the lowest possible osmolality. It is a reproducible profile that remains within the approved product specifications and performs consistently across manufacturing lots and storage conditions.

Container-closure selection

Flexible bags can improve pharmacy workflow and reduce the need for transfer steps. They also create technical challenges involving:

• Drug adsorption or permeation
• Moisture loss
• Oxygen transmission
• Seal integrity
• Port performance
• Film-layer compatibility
• Extractables and leachables
• Light exposure

A multilayer polyolefin or other approved flexible-container system may be commercially attractive, but the container is part of the formulation platform. A change in bag film, port, overwrap, or sterilization process can require substantial comparability data.

Stability and storage

Longer shelf life improves inventory economics and helps hospitals manage emergency-department and intensive-care-unit stock. Stability work should cover:

• Long-term storage
• Accelerated conditions
• In-use administration periods
• Dilution or transfer, if permitted
• Light exposure
• Freeze-thaw exposure where relevant
• Container orientation
• Particulate formation
• Subvisible particles
• pH drift
• Assay and degradation products

For a mature generic, a reliable 24-month shelf life can have more commercial value than a novel excipient claim.

What patents protect levetiracetam in sodium chloride injection?

The primary levetiracetam molecule is a mature small-molecule compound. The principal composition-of-matter and reference-product exclusivity periods have expired in the United States. Generic competition is established.

The practical patent position has several layers:

Protection category	Current commercial significance
Levetiracetam composition-of-matter patents	Generally expired
Reference-product regulatory exclusivity	Expired
Oral formulation patents	Generally limited relevance to the premixed IV product
IV dosage-form patents	Must be checked product by product
Method-of-use patents	Potentially relevant if listed, but often narrow for generic launch analysis
Container or manufacturing patents	May create process constraints, but usually do not block all generic approaches
Hospital-use or packaging claims	Potential commercial differentiation, rarely broad market exclusivity

The absence of broad active-ingredient protection does not mean that every formulation is risk-free. A manufacturer still must review active U.S. patents, Orange Book-listed patents, non-Orange-Book formulation patents, and litigation records before filing or launch.

How many patents cover levetiracetam injection?

There is no reliable single number without defining the jurisdiction, reference product, filing date, and whether expired or unasserted patents are counted. For commercial planning, the relevant question is whether an unexpired patent could support an infringement claim against the proposed formulation, manufacturing process, labeling, or container system.

The FDA Orange Book should be reviewed for the reference product and any listed patents. Patent claims that cover oral tablets, oral solutions, or unrelated dosage forms may have little relevance to a ready-to-use IV sodium chloride bag.[4]

When does levetiracetam lose exclusivity?

U.S. exclusivity for levetiracetam has already expired. The market is therefore controlled by generic approval, manufacturing reliability, pricing, supply agreements, and hospital formulary access rather than by branded exclusivity.

Milestone	Commercial implication
Original Keppra approval	Established the reference product
Expiration of active-ingredient and regulatory protections	Enabled generic entry
Generic IV approvals	Shifted purchasing power to hospitals and group purchasing organizations
Current market	Mature, price-sensitive, multi-supplier market

Because the product is a small molecule, biosimilar pathways do not apply. Competitors file ANDAs, not biosimilar applications. FDA review focuses on pharmaceutical equivalence, bioequivalence where applicable, product quality, sterility, manufacturing controls, and labeling.

Are Paragraph IV challenges relevant to levetiracetam injection?

Paragraph IV certifications were relevant when generic applicants challenged unexpired listed patents. For a mature levetiracetam IV product, new Paragraph IV activity is less likely to determine the market than abbreviated applications relying on expired patents, certification pathways, or patent statements reflecting the current Orange Book.

A Paragraph IV filing can create litigation exposure if an applicant alleges that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The commercial value of such a challenge depends on:

• The remaining patent term
• The likelihood of a 30-month stay
• The number of competing ANDA filers
• The strength of the patent claims
• The potential first-filer position
• The size of the addressable market

For a low-priced hospital injectable, litigation economics can be unfavorable unless the challenger expects meaningful market share or a period of limited competition.

What FDA regulatory requirements apply?

Levetiracetam in sodium chloride injection is subject to the FDA’s requirements for sterile injectable drug products. The regulatory package must address the active ingredient, excipients, manufacturing process, container-closure system, sterility, endotoxins, particulate matter, stability, and labeling.

Critical regulatory areas include:

1. Pharmaceutical equivalence to the reference product.
2. Consistent strength and concentration.
3. Sterility assurance and container-closure integrity.
4. Bacterial endotoxin control.
5. Visible and subvisible particulate limits.
6. Compatibility with the proposed administration system.
7. Extractables and leachables assessment.
8. Stability through the proposed expiration period.
9. Validated analytical methods for assay and degradation products.
10. Adequate process controls for aseptic processing or terminal sterilization.

FDA guidance for sterile drug products places substantial emphasis on facility design, aseptic processing, environmental monitoring, media fills, personnel qualification, and contamination-control strategy.[5]

What commercial opportunities exist for levetiracetam injection?

The strongest opportunities are supply-chain and workflow opportunities.

Hospital-ready premixed bags

A ready-to-use bag can compete against vials or concentrates by reducing preparation steps. The value proposition is strongest in emergency departments, intensive-care units, perioperative settings, and hospitals with high anticonvulsant utilization.

Contract-manufacturing and private-label supply

A manufacturer with sterile injectable capacity can supply wholesalers, regional hospital systems, and group purchasing organizations. Private-label production can provide volume without requiring a large commercial field force.

Dual-source and shortage-resilience contracts

Hospitals may pay a premium, or accept less aggressive pricing, for dependable secondary supply. The FDA Drug Shortages Database and hospital procurement history can identify periods when injectable supply reliability creates purchasing leverage.[6]

Packaging differentiation

Commercial differentiation may include:

• Smaller-volume bags
• Multiple strengths
• Latex-free components
• Barcoded unit-of-use packaging
• Overwraps that improve light protection
• Clear labeling for loading-dose use
• Ready-to-administer formats
• Reduced overfill
• Improved port design

These attributes generally support purchasing preference rather than regulatory exclusivity.

International markets

Outside the United States, opportunity depends on local registration, hospital procurement rules, pricing controls, and tender access. Europe, Canada, Latin America, and selected emerging markets may favor products with validated flexible bags and long shelf life. However, geographic expansion requires separate assessments of local reference products, data requirements, pharmacopoeial standards, language labeling, and import controls.

What manufacturing and IP barriers affect entry?

The largest barriers are usually operational.

Barrier	Entry effect
Sterile injectable facility capacity	Can delay development and limit launch scale
Flexible-bag filling technology	Requires specialized equipment and validation
Container-closure integrity	Can create batch-release or stability failures
Extractables and leachables	May require extensive packaging studies
Low gross margins	Limits tolerance for manufacturing inefficiency
API supply concentration	Creates cost and continuity risk
Hospital tenders	Can force rapid price reductions
Product recalls	Can damage formulary access and supply contracts

Manufacturing patents may matter where a competitor uses a proprietary filling process, container technology, or packaging configuration. In many cases, the entrant can design around such claims by using a different bag film, fill volume, sterilization method, or process sequence. Freedom-to-operate analysis should cover both product claims and process claims.

How strong is the patent estate for levetiracetam in sodium chloride?

The patent estate is weak as a basis for long-term market exclusivity but manageable as a freedom-to-operate matter.

Factor	Assessment
Active-ingredient protection	Low
Regulatory exclusivity	Expired
IV formulation protection	Potentially narrow and claim-specific
Method-of-use protection	Generally limited commercial impact for standard IV use
Container and process patents	Relevant to design-around analysis
Biosimilar risk	None
Generic competition	High
Pricing power	Low to moderate
Supply-chain differentiation	Moderate to high

The commercial strategy should focus on product execution rather than patent monetization.

What litigation and settlement risks affect generic launch?

Litigation risk is typically lower than for recently approved branded drugs, but it is not zero. Risk can arise from:

• Paragraph IV certification
• Orange Book patent disputes
• Non-Orange-Book formulation patents
• Trade-secret claims involving manufacturing
• Patent claims directed to bags or closure systems
• Contract disputes involving authorized generic supply
• Product-quality or recall litigation

Settlement agreements can affect launch timing, but their economic value depends on whether a branded company still has meaningful market share or whether the market is already crowded with generic suppliers. A settlement that delays entry may have limited value where several other generic products are already available.

How does levetiracetam injection compare with competing anticonvulsant injectables?

Product	Formulation complexity	Generic competition	Key commercial issue
Levetiracetam injection	Low to moderate	High	Price and supply reliability
Fosphenytoin injection	Moderate to high	Moderate	Compatibility, dosing, and tolerability
Phenytoin injection	High	High	Administration constraints and safety concerns
Valproate sodium injection	Moderate	High	Broad hospital use and safety monitoring
Lacosamide injection	Moderate	Increasing	Newer product lifecycle and price erosion
Brivaracetam injection	Moderate	Lower than levetiracetam	Brand-to-generic transition timing

Levetiracetam has a favorable operational profile because it does not require the same level of formulation complexity or administration management associated with phenytoin. Its weakness is intense price competition and limited patent leverage.

What revenue exposure and launch scenarios should investors model?

Revenue depends more on contracted volume and manufacturing utilization than on branded pricing.

Base-case scenario

A new entrant launches into a multi-generic market, wins limited hospital contracts, and competes on supply reliability. Gross margins decline as additional suppliers enter.

Upside scenario

The entrant has qualified sterile-bag capacity, obtains group purchasing organization contracts, offers several strengths, and captures share during competitor shortages or manufacturing disruptions.

Downside scenario

The entrant experiences approval delay, container-closure problems, API cost inflation, or failed hospital tenders. Low market prices then make remediation or relaunch uneconomic.

Key commercial metrics include:

• Approved strengths
• Monthly production capacity
• Fill-finish yield
• Cost per bag
• API cost as a percentage of cost of goods
• Contracted hospital volume
• Wholesale acquisition price
• Average selling price after rebates
• Number of qualified suppliers
• Back-order frequency
• Product-shortage exposure
• Shelf-life remaining at shipment

For a mature injectable, reliable supply and low defect rates can produce more value than incremental formulation claims.

Key Takeaways

• Levetiracetam in sodium chloride injection is a mature, genericized sterile injectable.
• The excipient platform is intentionally simple and generally centers on sodium chloride, Water for Injection, and pH adjusters.
• The strongest development opportunities are ready-to-use bags, multiple concentrations, long shelf life, barcoding, and dependable supply.
• Broad composition-of-matter exclusivity and reference-product exclusivity have expired.
• Orange Book and freedom-to-operate review remain necessary for product, process, method-of-use, and container claims.
• Paragraph IV litigation is less likely to define the current market than manufacturing reliability and hospital contracting.
• Biosimilar risk does not apply because levetiracetam is a small-molecule drug.
• The principal entry barriers are sterile manufacturing, packaging validation, quality systems, API supply, and low-margin hospital pricing.
• Commercial success depends on cost-efficient fill-finish operations, shortage resilience, and procurement access.

FAQs

Is sodium chloride the only meaningful excipient in levetiracetam injection?

No. The product may also contain Water for Injection and small quantities of hydrochloric acid or sodium hydroxide for pH adjustment. The precise inactive-ingredient list is product-specific.

Can a company patent a new levetiracetam infusion bag?

Potentially, but patentability would depend on novelty, non-obviousness, enablement, and claim scope. A routine bag-size or concentration change is unlikely to create strong protection without a technical advantage.

Does levetiracetam injection require a biosimilar application?

No. Levetiracetam is a small molecule. A competing U.S. product generally follows the ANDA pathway rather than the biosimilar pathway.

What is the most valuable formulation improvement?

For hospital customers, the highest-value improvements are usually reduced preparation steps, dependable container performance, long shelf life, clear labeling, and consistent availability.

Can a generic manufacturer obtain meaningful exclusivity for levetiracetam injection?

Meaningful exclusivity is difficult in the current market. Commercial advantage is more likely to come from supply contracts, differentiated packaging, shortage-period availability, or a specialized regulatory pathway than from broad patent exclusivity.

References

1. U.S. Food and Drug Administration. (2024). Keppra (levetiracetam) injection prescribing information. FDA/DailyMed.

2. U.S. National Library of Medicine. (2024). Levetiracetam injection product labeling. DailyMed.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda

5. U.S. Food and Drug Administration. (2004). Sterile drug products produced by aseptic processing: Current good manufacturing practice guidance for industry. https://www.fda.gov/

6. U.S. Food and Drug Administration. (2024). FDA drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/